相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Role of osteopontin in dendritic cell shaping of immune responses
Annalisa Del Prete et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2019)
Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549)
Jasmin Kharazmi-Khorassani et al.
ENVIRONMENTAL TOXICOLOGY (2019)
Modulating inflammation for cancer therapy
Birgit Ritter et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Elisabeth Perez-Ruiz et al.
NATURE (2019)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade
Feng Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Immunomodulatory and enhanced antitumor activity of a modified thymosin α1 in melanoma and lung cancer
Fanwen Wang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2018)
Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management
Mark A. Samaan et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
The Cancer Immunotherapy Revolution
Priscilla N. Kelly
SCIENCE (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
Laurence Zitvogel et al.
SCIENCE (2018)
Effect of a C-end rule modification on antitumor activity of thymosin α1
Fanwen Wang et al.
BIOCHIMIE (2018)
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy
Riccardo Danielli et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study
Xiaoning Wu et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life
Fanwen Wang et al.
SCIENTIFIC REPORTS (2018)
Thymosin α1 suppresses migration and invasion o f PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signaling
Cong Bo et al.
ONCOTARGETS AND THERAPY (2018)
Thymalfasin, a promising adjuvant therapy in small hepatocellular carcinoma after liver resection
Chao He et al.
MEDICINE (2017)
Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis
Luigina Romani et al.
NATURE MEDICINE (2017)
Skewing of the population balance of lymphoid and myeloid cells by secreted and intracellular osteopontin
Masashi Kanayama et al.
NATURE IMMUNOLOGY (2017)
Thymosin 1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study
Yong-Rong Liang et al.
ONCOLOGY LETTERS (2016)
Thymosin α1 promotes the activation of myeloid-derived suppressor cells in a Lewis lung cancer model by upregulating Arginase 1
Chao Yuan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Evaluation of thymosin α 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis
Robert S King et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy
Michelle N. Messmer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Intracellular Osteopontin Inhibits Toll-like Receptor Signaling and Impedes Liver Carcinogenesis
Xiaoyu Fan et al.
CANCER RESEARCH (2015)
Classification of current anticancer immunotherapies
Lorenzo Galluzzi et al.
ONCOTARGET (2014)
The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2
Juan Li et al.
CANCER LETTERS (2013)
A Tumor-Penetrating Peptide Modification Enhances the Antitumor Activity of Thymosin Alpha 1
Xingzhen Lao et al.
PLOS ONE (2013)
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond
Riccardo Danielli et al.
THYMOSINS IN HEALTH AND DISEASE II (2012)
Immunotherapy of cancer in 2012
John M. Kirkwood et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role?
A. Ciancio et al.
JOURNAL OF VIRAL HEPATITIS (2012)
Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study
Bo Hyun Kim et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2012)
Intracellular osteopontin (iOPN) and immunity
Makoto Inoue et al.
IMMUNOLOGIC RESEARCH (2011)
Expression, Purification and Characterization of A Novel Soluble Human Thymosin Alpha1 Concatemer Exhibited A Stronger Stimulation on Mice Lymphocytes Proliferation and Higher Anti-tumor Activity
Weina Li et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2011)
Thymosin plus cisplatin with vinorelbine or gemcitabine for non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials
Jin Jiang et al.
THORACIC CANCER (2011)
Large Randomized Study of Thymosin α 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma
Michele Maio et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hepatocellular carcinoma: a global view
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma
Robert G. Gish et al.
HEPATOLOGY INTERNATIONAL (2009)
Treatment with lamivudine versus lamivudine and thymosin alpha-I for e antigen-positive chronic hepatitis B patients: a meta-analysis
Yuan-Yuan Zhang et al.
VIROLOGY JOURNAL (2009)
Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis
Yuan-Yuan Zhang et al.
VIROLOGY JOURNAL (2009)
Efficacy of triple therapy with thymalfasin, peginterferon α-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders
Jorge L. Poo et al.
ANNALS OF HEPATOLOGY (2008)
Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment
Yang Hyun Baek et al.
GUT AND LIVER (2007)
Thymosin α1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance
Luigina Romani et al.
BLOOD (2006)
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment:: 24-week interim results of a pilot study
JL Poo et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment:: 24-week interim results of a pilot study
JL Poo et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial
P Andreone et al.
JOURNAL OF VIRAL HEPATITIS (2004)
Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B
M Saruc et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2003)
Thymosin-α1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
GKK Lau et al.
JOURNAL OF VIRAL HEPATITIS (2002)
In vitro effect of thymosin-α1 and interferon-α on Th1 and Th2 cytokine synthesis in patients with chronic hepatitis C
P Andreone et al.
JOURNAL OF VIRAL HEPATITIS (2001)
Thymosinα1 is chemopreventive for lung adenoma formation in A/J mice
TW Moody et al.
CANCER LETTERS (2000)
A randomized, controlled study of thymosin-α1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B
C Zavaglia et al.
DIGESTIVE DISEASES AND SCIENCES (2000)
Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma
G Rasi et al.
MELANOMA RESEARCH (2000)
分享论文
